今日盘中，微创脑科学（02172.HK）股价大跌5.38%，引发市场关注。这一显著跌幅主要源于公司最新公布的2025年中期业绩不及预期。
根据微创脑科学发布的2025年中期业绩报告，公司收入约3.83亿元人民币，同比下降6.2%；公司权益股东应占溢利为9292.3万元人民币，同比大幅减少35.25%。每股盈利降至0.16元人民币，公司宣布派发中期股息5港仙，较去年同期的8港仙有所下调。
业绩下滑主要受两方面因素影响：一是集中采购政策影响了出血性脑卒中产品的销售，导致该类产品收入下降5.5%至2.34亿元人民币；二是原代理产品停止合作，致使脑动脉粥样硬化狭窄产品收入下降11.5%至1.15亿元人民币。尽管如此，公司国际业务表现亮眼，海外收入达4710万元人民币，同比增长67.4%，显示出公司在国际市场的扩张潜力。然而，这一亮点似乎未能抵消投资者对整体业绩下滑的担忧，导致股价出现明显跌幅。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.